References
- WHO Report. Rotavirus surveillance – worldwide, 2009. Wkly Epidemiol. Rec. 86, 174–176 (2011).
- Koo H, Ajami N, Atmar R, DuPont H. Noroviruses: the principal cause of foodborne disease worldwide. Discov. Med. 10, 61–70 (2010).
- O'Ryan M, Peña A, Vergara R et al. Prospective characterization of norovirus compared with rotavirus acute diarrhea episodes in Chilean children. Pediatr. Infect. Dis. J. 29, 855–859 (2010).
- Teunis P, Moe C, Liu P et al. Norwalk virus: how infectious is it? J. Med. Virol. 80, 1468–1476 (2008).
- Lodder W, van den Berg H, Rutjes S, de Roda Husman A. Presence of enteric viruses in source waters for drinking water production in The Netherlands. Appl. Environ. Microbiol. 76, 5965–5971 (2010).
- Kiulia N, Netshikweta R, Page N et al. The detection of enteric viruses in selected urban and rural river water and sewage in Kenya, with special reference to rotaviruses. J. Appl. Microbiol. 109, 818–828 (2010).
- Yoder J, Roberts V, Craun G et al. Surveillance for waterborne disease and outbreaks associated with drinking water and water not intended for drinking – United States, 2005–2006. MMWR Surveill. Summ. 57, 39–62 (2008).
- Bucardo F, Lindgren P, Svensson L, Nordgren J. Low prevalence of rotavirus and high prevalence of norovirus in hospital and community wastewater after introduction of rotavirus vaccine in Nicaragua. PLoS One 6(10), e25962 (2011).
- O'Ryan M, Lucero Y, Linhares A. Rotarix®: vaccine performance 6 years postlicensure. Expert Rev. Vaccines 10(12), 1645–1659 (2011).
- Goveia M, Ciarlet M, Owen K, Ranucci C. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine. Ann. NY Acad. Sci. 1222, 14–18 (2011).
- Prado T, Silva D, Guilayn W et al. Quantification and molecular characterization of enteric viruses detected in effluents from two hospital wastewater treatment plants. Water Res. 45, 1287–1297 (2011).
- Sáfadi M, Berezin E, Munford V et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in São Paulo, Brazil. Pediatr. Infect. Dis. J. 29, 1019–1022 (2010).
- Lanzieri T, Costa I, Shafi F et al. Trends in hospitalizations from all-cause gastroenteritis in children younger than 5 years of age in Brazil before and after human rotavirus vaccine introduction, 1998–2007. Pediatr. Infect. Dis. J. 29, 673–675 (2010).
- Linhares A, Velázquez F, Pérez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled Phase III study. Lancet 371, 1181–1189 (2008).
- Madhi S, Cunliffe N, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 362, 289–298 (2010).
- O'Ryan M, Lucero Y, Prado V et al. Symptomatic and asymptomatic rotavirus and norovirus infections during infancy in a Chilean birth cohort. Pediatr. Infect. Dis. J. 28, 879–884 (2009).
- Phillips G, Lopman B, Rodrigues L, Tam C. Asymptomatic rotavirus infections in England: prevalence, characteristics, and risk factors. Am. J. Epidemiol. 171, 1023–1030 (2010).
- Lopman B, Curns A, Yen C, Parashar U. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J. Infect. Dis. 204, 980–986 (2011).
- Fumian T, Leite J, Rose T, Prado T, Miagostovich M. One year environmental surveillance of rotavirus specie A (RVA) genotypes in circulation after the introduction of the Rotarix® vaccine in Rio de Janeiro, Brazil. Water Res. 45, 5755–5763 (2011).
- Newell D, Koopmans M, Verhoef L et al. Food-borne diseases – the challenges of 20 years ago still persist while new ones continue to emerge. Int. J. Food Microbiol. 139, S3–S15 (2010).
- Uhrbrand K, Myrmel M, Maunula L et al. Evaluation of a rapid method for recovery of norovirus and hepatitis A virus from oysters and blue mussels. J. Virol. Methods. 169, 70–78 (2010).